Trial Profile

A phase 3 study of tarlatamab in earlier lines of small cell lung cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarlatamab (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

10 Aug 2023 New trial record
03 Aug 2023 According to an Amgen media release, company plans to initiate two phase 3 studies of Tarlatamab in earlier lines of small cell lung cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com